A study evaluating efficacy and safety of sofosbuvir and daclatasvir based therapy in hepatitis C virus genotype 3 patients with or without cirrhosis in India.
Latest Information Update: 25 May 2017
Price :
$35 *
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017